PLoS ONE (Jan 2015)

Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites.

  • Remko Schats,
  • Else M Bijker,
  • Geert-Jan van Gemert,
  • Wouter Graumans,
  • Marga van de Vegte-Bolmer,
  • Lisette van Lieshout,
  • Mariëlle C Haks,
  • Cornelus C Hermsen,
  • Anja Scholzen,
  • Leo G Visser,
  • Robert W Sauerwein

DOI
https://doi.org/10.1371/journal.pone.0124243
Journal volume & issue
Vol. 10, no. 5
p. e0124243

Abstract

Read online

Sterile protection in >90% of volunteers against homologous Plasmodium falciparum infection has been achieved only using the controlled human malaria infection (CHMI) model. This efficient model involves whole parasite immunizations under chloroquine prophylaxis (CPS-immunization), requiring only 30-45 mosquitoes bites infected with P. falciparum-sporozoites. Given the large diversity of P. falciparum parasites, it is essential to assess protection against heterologous parasite strains.In an open-label follow-up study, 16 volunteers previously CPS-immunized and challenged with P. falciparum NF54 (West-Africa) in a dose de-escalation and challenge trial were re-challenged with clone NF135.C10 (Cambodia) at 14 months after the last immunization (NCT01660854).Two out of thirteen NF54 protected volunteers previously fully protected against NF54 were also fully protected against NF135.C10, while 11/13 showed a delayed patency (median prepatent period of 10.5 days (range 9.0-15.5) versus 8.5 days in 5 malaria-naïve controls (p = 0.0005). Analysis of patency by qPCR indicated a 91 to >99% estimated reduction of liver parasite load in 7/11 partially protected subjects. Three volunteers previously not protected against NF54, were also not protected against NF135.C10.This study shows that CPS-immunization can induce heterologous protection for a period of more than one year, which is a further impetus for clinical development of whole parasite vaccines.Clinicaltrials.gov NCT01660854.